Technical note: Characterization of a multi‐point scintillation dosimetry research platform for a low‐field MR‐Linac
Medical Physics · 2024
DOI: 10.1002/mp.17192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Physics, 2024. Verfasst von Jennie Crosby und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Magnetic Resonance Imaging, Particle Accelerators, Scintillation Counting, Radiometry. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
Background
MRI‐guided radiation therapy (MRgRT) requires unique quality assurance equipment to address MR‐compatibility needs, minimize electron return effect, handle complex dose distributions, and evaluate real‐time dosimetry for gating. Plastic scintillation detectors (PSDs) are an attractive option to address these needs.
Purpose
To perform a comprehensive characterization of a multi‐probe PSD system in a low‐field 0.35 T MR‐linac, including detector response assessment and gating performance.
Methods
A four‐channel PSD system (HYPERSCINT RP‐200) was assembled. A single channel was used to evaluate repeatability, percent depth dose (PDD), detector response as a function of orientation with respect to the magnetic field, and intersession variability. All four channels were used to evaluate repeatability, linearity, and output factors. The four PSDs were integrated into an MR‐compatible motion phantom at isocenter and in gradient regions. Experiments were conducted to evaluate gating performance and tracking efficacy.
Results
For repeatability, the maximum standard deviation of repeated measurements was 0.13% (single PSD). Comparing the PSD to reference data, PDD had a maximum difference of 1.12% (10 cm depth, 6.64 × 6.64 cm 2 ). Percent differences for rotated detector setups were negligible (< 0.3%). All four PSDs demonstrated linear response over 10–1000 MU delivered and the maximum percent difference between the baseline and measured output factors was 0.78% (2.49 × 2.49 cm 2 ). Gating experiments had 400 cGy delivered to isocenter with < 0.8 cGy variation for central axis measures and < 0.7 cGy for the gradient sampled region. Real‐time dosimetry measurements captured spurious beam‐on incidents that correlated to tracking algorithm inaccuracies and highlighted gating parameter impact on delivery efficiency.
Conclusions
Characterization of the multi‐point PSD dosimetry system in a 0.35 T MR‐linac demonstrated reliability in a low‐field MR‐Linac setting, with high repeatability, linearity, small intersession variability, and similarity to baseline data for PDD and output factors. Time‐resolved, multi‐point dosimetry also showed considerable promise for gated MR‐Linac applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
- Medscint, Québec, Canada.
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
- NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Crosby, J., Ruff, C., Gregg, K., Turcotte, J., & Glide-Hurst, C. (2024). Technical note: Characterization of a multi‐point scintillation dosimetry research platform for a low‐field MR‐Linac. Medical Physics. https://doi.org/10.1002/mp.17192
Vancouver
Crosby J, Ruff C, Gregg K, Turcotte J, Glide-Hurst C. Technical note: Characterization of a multi‐point scintillation dosimetry research platform for a low‐field MR‐Linac. Medical Physics. 2024. doi:10.1002/mp.17192
BibTeX
@article{Crosby2024,
author = {Crosby, Jennie and Ruff, Chase and Gregg, Ken and Turcotte, Jonathan and Glide-Hurst, Carri},
title = {Technical note: Characterization of a multi‐point scintillation dosimetry research platform for a low‐field MR‐Linac},
journal = {Medical Physics},
year = {2024},
doi = {10.1002/mp.17192}
}
EUVIMED